Anhui Fengyuan Pharmaceutical Co., Ltd. (000153) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Anhui Fengyuan Pharmaceutical Co., Ltd.

Why is Anhui Fengyuan Pharmaceutical Co., Ltd. ?

The company is Net-Debt Free

Poor long term growth as Net Sales has grown by an annual rate of 1.70% and Operating profit at -3.15% over the last 5 years
The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 7.81% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 1.70% and Operating profit at -3.15% over the last 5 years

The company has declared Negative results for the last 9 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at CNY 124.82 MM
NET PROFIT(HY) At CNY 34.99 MM has Grown at -33.59%
INTEREST(HY) At CNY 16.48 MM has Grown at 5.27%

With ROE of 4.26%, it has a fair valuation with a 1.12 Price to Book Value

Over the past year, while the stock has generated a return of -10.12%, its profits have fallen by -37.1%
At the current price, the company has a high dividend yield of 0

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -10.12% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Anhui Fengyuan Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Anhui Fengyuan Pharmaceutical Co., Ltd.

-100.0%

-0.11

29.56%

China Shanghai Composite

20.18%

1.55

13.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.70%

EBIT Growth (5y)

-3.15%

EBIT to Interest (avg)

4.90

Debt to EBITDA (avg)

2.86

Net Debt to Equity (avg)

0.54

Sales to Capital Employed (avg)

1.25

Tax Ratio

20.12%

Dividend Payout Ratio

46.75%

Pledged Shares

Institutional Holding

ROCE (avg)

6.31%

ROE (avg)

7.81%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.12

EV to EBIT

32.52

EV to EBITDA

15.73

EV to Capital Employed

1.08

EV to Sales

0.98

PEG Ratio

Dividend Yield

ROCE (Latest)

3.32%

ROE (Latest)

4.26%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -9.12% (YoY

CASH AND EQV(HY)

Highest at CNY 857.48 MM

-23What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 124.82 MM

NET PROFIT(HY)

At CNY 34.99 MM has Grown at -33.59%

INTEREST(HY)

At CNY 16.48 MM has Grown at 5.27%

ROCE(HY)

Lowest at 4.63%

DEBT-EQUITY RATIO (HY)

Highest at 56.87 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.34 times

NET SALES(Q)

Fallen at -11.14%

OPERATING PROFIT(Q)

Lowest at CNY 43.33 MM

Here's what is working for Anhui Fengyuan Pharmaceutical Co., Ltd.

Cash and Eqv

Highest at CNY 857.48 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -9.12% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Anhui Fengyuan Pharmaceutical Co., Ltd.

Net Profit

At CNY 34.99 MM has Grown at -33.59%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Operating Cash Flow

Lowest at CNY 124.82 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 16.48 MM has Grown at 5.27%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

Fallen at -11.14%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY 43.33 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Debt-Equity Ratio

Highest at 56.87 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 3.34 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio